Menopause for NEET PG OBG: Definition, Stages, Hot Flushes, Genitourinary Syndrome, Hormone Therapy Rules and Non-hormonal Options

Start Here

🎯 Exam priority: Moderate–high. Expect: 12-month definition, average and premature/early ages, FSH role, hot flush facts, GSM and its local treatment, why a progestogen is added, the age/time window for starting hormone therapy, its risks, and non-hormonal alternatives.

CBME mapping: OG32.

Menopause definitions, symptoms, hormone therapy rules, non-hormonal options and genitourinary syndrome of menopause

Menopause definitions, symptoms, hormone therapy and alternatives. Drawn by TrackNation.

Definitions and Stages (MSD)

  • Menopause is diagnosed retrospectively after 12 months without menses; average age 51 (US), normal range 45–55. Smoking, high altitude and undernutrition bring it earlier.

  • Premature <40 (= primary ovarian insufficiency, treated with oestrogen-progestogen); early 40–45.

  • Perimenopause: years before and 1 year after the last period — the most symptomatic phase. The menopausal transition lasts about 4–8 years; late transition = gaps of ≥60 days, FSH >25 IU/L. FSH is rarely needed (e.g. after hysterectomy or at a young age).

  • Rule out pregnancy, other causes of amenorrhoea and uterine cancer in abnormal bleeding.

Symptoms (MSD)

  • Hot flushes/night sweats in 75–85%, usually starting before periods stop, lasting on average 7.4 years (sometimes >10).

  • Genitourinary syndrome of menopause (GSM): falling oestrogen → dryness, burning, dyspareunia, urgency, dysuria, recurrent UTIs. It is chronic; treatment must continue.

  • Others: sleep disturbance, mood change; long-term bone loss — screen bone density in women at high fracture risk.

Treatment (MSD)

  • Hormone therapy (HT) is the most effective treatment for symptoms. With a uterus, oestrogen must be combined with a progestogen (prevents endometrial neoplasia) — except very low-dose vaginal oestrogen; conjugated oestrogens + bazedoxifene need no progestogen.

  • Timing: benefits most likely exceed harms in healthy women <60 years or <10 years after menopause; starting >60 or >10–20 years after is generally not recommended (more coronary disease).

  • Risks: breast cancer rises after 3–5 years of combined therapy (oestrogen alone: slightly lower at 7 years in WHI); VTE and stroke lower with low-dose transdermal oestrogen. HT reduces bone loss and fractures.

  • Non-hormonal (all less effective than HT): fezolinetant (neurokinin-3 antagonist; check LFTs), elinzanetant (NK1/NK3), SSRIs/SNRIs, gabapentin, oxybutynin. Raloxifene for bone protection in women at high breast-cancer risk.

  • GSM: lubricants and moisturisers; first-line drugs — low-dose vaginal oestrogen, vaginal DHEA (prasterone) or ospemifene (oral SERM; VTE risk).

Traps the Examiner Sets

  • Menopause is a clinical, retrospective diagnosis — not an FSH diagnosis.

  • Oestrogen alone is only for women without a uterus (vaginal low dose excepted).

  • Starting HT after 60 or long after menopause is not advised.

  • Premature menopause is before 40; early is 40–45.

Memory Hooks & Shortcuts

Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.

  • 🧠 '12 months, 51 years, 40 premature, 45 early' — definitions

  • 🧠 'Uterus = add Progestogen' (vaginal low-dose oestrogen excepted) — HT

  • 🧠 HT window '60 or 10': under 60 or within 10 years — timing

  • 🧠 'Patch protects' — transdermal oestrogen means less clotting and stroke — route

  • 🧠 Fezolinetant: 'NK3 blocks the hot flush, check the liver' — non-hormonal

Rapid-Revision Cards

  • Definition

    12 months no menses.

  • Average age

    51 (normal 45–55).

  • Premature

    <40.

  • Early

    40–45.

  • Earlier with

    Smoking, altitude, undernutrition.

  • FSH test

    Rarely needed.

  • Late transition

    ≥60-day gaps; FSH >25.

  • Hot flushes

    75–85%; ~7.4 y.

  • GSM

    Dryness, dyspareunia, urgency.

  • Best for symptoms

    Hormone therapy.

  • Uterus present

    Add progestogen.

  • Exception

    Low-dose vaginal oestrogen.

  • CE + bazedoxifene

    No progestogen needed.

  • HT window

    <60 or <10 y.

  • Don't start

    >60 or >10–20 y.

  • Breast risk

    After 3–5 y combined.

  • Safer route

    Transdermal (VTE, stroke).

  • Fezolinetant

    NK3 antagonist; LFTs.

  • GSM drugs

    Vaginal E, DHEA, ospemifene.

  • Bone + breast risk

    Raloxifene.

  • POI

    E + P therapy.

Sources

Facts in this article were checked against these documents.

  • MSD Manual Professional: Menopause; Genitourinary Syndrome of Menopause; Primary Ovarian Insufficiency — Merck & Co. (MSD Manuals), 2025–26 (link)

  • Competency Based Undergraduate Curriculum, Vol III: Obstetrics & Gynaecology (OG32) — National Medical Commission, 2024

Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

Practice Questions (NEET PG pattern)

Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.

Q1. Menopause is diagnosed when there has been no menstruation for

  • (a) 6 months

  • (b) 12 months

  • (c) 3 months

  • (d) 24 months

Show answer

Answer: (b) — Retrospective.


Q2. The average age of natural menopause (MSD, US data) is

  • (a) 40 years

  • (b) 51 years

  • (c) 55 years

  • (d) 45 years

Show answer

Answer: (b) — Normal 45–55.


Q3. A factor that makes menopause occur earlier is

  • (a) oral contraceptive use

  • (b) multiparity

  • (c) smoking

  • (d) obesity

Show answer

Answer: (c) — Also altitude, undernutrition.


Q4. Menopause at 38 years is termed

  • (a) normal

  • (b) early

  • (c) premature (primary ovarian insufficiency)

  • (d) late

Show answer

Answer: (c) — <40.


Q5. Menopause at 43 years is termed

  • (a) normal

  • (b) early

  • (c) late

  • (d) premature

Show answer

Answer: (b) — 40–45.


Q6. A 50-year-old with 12 months of amenorrhoea and hot flushes asks for an FSH test. MSD says FSH is

  • (a) needed monthly

  • (b) rarely necessary — diagnosis is clinical

  • (c) mandatory

  • (d) the only way to diagnose

Show answer

Answer: (b) — Except after hysterectomy/young.


Q7. Hot flushes affect about

  • (a) 75–85% of women

  • (b) 100%

  • (c) 5%

  • (d) 25%

Show answer

Answer: (a) — Average 7.4 years.


Q8. Vasomotor symptoms last on average

  • (a) 6 months

  • (b) 7.4 years

  • (c) 1 month

  • (d) 20 years always

Show answer

Answer: (b) — Can exceed 10 years.


Q9. Hot flushes usually begin

  • (a) only 5 years after menopause

  • (b) before periods stop

  • (c) never in perimenopause

  • (d) only after surgery

Show answer

Answer: (b) — MSD.


Q10. The late menopausal transition is marked by

  • (a) regular cycles

  • (b) amenorrhoea of ≥60 days and FSH >25 IU/L

  • (c) low FSH

  • (d) heavy regular periods

Show answer

Answer: (b) — STRAW-type staging.


Q11. The most effective treatment for menopausal vasomotor symptoms is

  • (a) SSRIs

  • (b) black cohosh

  • (c) hormone therapy

  • (d) gabapentin

Show answer

Answer: (c) — MSD.


Q12. A 52-year-old with an intact uterus starts systemic oestrogen. She must also take

  • (a) a progestogen

  • (b) testosterone

  • (c) nothing else

  • (d) thyroxine

Show answer

Answer: (a) — Prevents endometrial neoplasia.


Q13. Which oestrogen can be used without a progestogen in a woman with a uterus?

  • (a) oral conjugated oestrogen 0.625 mg alone

  • (b) transdermal oestradiol patch alone

  • (c) very low-dose vaginal oestrogen for GSM

  • (d) any oestrogen

Show answer

Answer: (c) — Also CE + bazedoxifene.


Q14. Conjugated oestrogens can be given without a progestogen when combined with

  • (a) tamoxifen

  • (b) bazedoxifene

  • (c) clomiphene

  • (d) letrozole

Show answer

Answer: (b) — A SERM.


Q15. Benefits of HT most likely outweigh harms in healthy symptomatic women who are

  • (a) over 70

  • (b) any age equally

  • (c) 20 years past menopause

  • (d) under 60 or within 10 years of menopause

Show answer

Answer: (d) — Timing window.


Q16. A 68-year-old, 18 years post-menopause, asks to start HT for prevention. MSD advice:

  • (a) generally not recommended

  • (b) mandatory for bone

  • (c) start high-dose oestrogen

  • (d) start oral HT at once

Show answer

Answer: (a) — More coronary risk.


Q17. Breast cancer risk with standard combined HT begins to rise after about

  • (a) 1 month

  • (b) 20 years

  • (c) it never rises

  • (d) 3–5 years

Show answer

Answer: (d) — MSD.


Q18. VTE and stroke risk with HT may be lower with

  • (a) injectable oestrogen

  • (b) oral oestrogen with tamoxifen

  • (c) high-dose oral oestrogen

  • (d) low-dose transdermal oestrogen

Show answer

Answer: (d) — MSD.


Q19. In WHI, oestrogen-alone therapy in women without a uterus

  • (a) doubled breast cancer

  • (b) had no data

  • (c) caused endometrial cancer

  • (d) slightly lowered breast cancer risk at 7 years

Show answer

Answer: (d) — Benefit faded later.


Q20. HT in postmenopausal women

  • (a) increases fractures

  • (b) causes osteomalacia

  • (c) reduces bone loss and fractures

  • (d) has no bone effect

Show answer

Answer: (c) — MSD.


Q21. Fezolinetant treats hot flushes by

  • (a) blocking dopamine

  • (b) blocking neurokinin-3 receptors

  • (c) replacing oestrogen

  • (d) blocking serotonin reuptake

Show answer

Answer: (b) — Check LFTs.


Q22. Before starting fezolinetant you must check

  • (a) bone density

  • (b) serum calcium

  • (c) TSH

  • (d) liver function tests

Show answer

Answer: (d) — Then 3-monthly.


Q23. Non-hormonal drugs for hot flushes, compared with HT, are

  • (a) equally effective always

  • (b) more effective

  • (c) contraindicated

  • (d) less effective

Show answer

Answer: (d) — MSD.


Q24. A breast cancer survivor wants non-hormonal relief of hot flushes. Options include

  • (a) systemic oestrogen

  • (b) SSRIs/SNRIs, gabapentin or a neurokinin antagonist

  • (c) tibolone

  • (d) testosterone

Show answer

Answer: (b) — MSD list.


Q25. Vaginal dryness, dyspareunia and urinary urgency after menopause are called

  • (a) Asherman syndrome

  • (b) PMOS

  • (c) genitourinary syndrome of menopause

  • (d) vaginismus

Show answer

Answer: (c) — Oestrogen deficiency.


Q26. First-line drug treatments for moderate–severe GSM include

  • (a) GnRH agonists

  • (b) low-dose vaginal oestrogen, vaginal DHEA or ospemifene

  • (c) danazol

  • (d) oral antibiotics

Show answer

Answer: (b) — Plus lubricants.


Q27. GSM treatment should be

  • (a) avoided

  • (b) stopped after symptoms settle

  • (c) given for 1 week only

  • (d) continued long term (chronic condition)

Show answer

Answer: (d) — Recurs on stopping.


Q28. Ospemifene is an oral SERM that carries a risk of

  • (a) hyperkalaemia

  • (b) lactic acidosis

  • (c) hypoglycaemia

  • (d) venous thrombosis

Show answer

Answer: (d) — MSD.


Q29. A postmenopausal woman at high breast cancer risk needs fracture prevention. MSD mentions

  • (a) systemic oestrogen alone

  • (b) progestogen alone

  • (c) raloxifene

  • (d) tamoxifen for bone

Show answer

Answer: (c) — SERM.


Q30. A 35-year-old with primary ovarian insufficiency should usually receive

  • (a) no treatment

  • (b) progestogen only

  • (c) clomiphene

  • (d) combined oestrogen-progestogen therapy

Show answer

Answer: (d) — Until natural menopause age.

Active Recall

From memory: define menopause and its premature and early forms, describe stages and symptoms including GSM, state hormone therapy rules, timing and risks, and list non-hormonal and local treatments.